Zealand Pharma A/S (NASDAQ: ZEAL) presented additional data from its Phase 2 ZUPREME-1 trial evaluating petrelintide for weight management at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE